Cargando…

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial

PURPOSE: The purpose of this analysis of patient-reported outcomes from the ELECT (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to explore the effect of lanreotide on symptoms of carcinoid syndrome. Specifically, this post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blot, Koenraad, Duchateau, Luc, Lescrauwaet, Benedicte, Liyanage, Nilani, Ray, David, Mirakhur, Beloo, Vinik, Aaron I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825468/ https://www.ncbi.nlm.nih.gov/pubmed/31754316 http://dx.doi.org/10.2147/PROM.S219982

Ejemplares similares

Patient-reported outcomes of ocriplasmin for the treatment of vitreomacular traction: a systematic review and synthesis of the literature
por: Lescrauwaet, Benedicte, et al.
Publicado: (2019)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Effectiveness of ocriplasmin in real‐world settings: A systematic literature review, meta‐analysis, and comparison with randomized trials
por: Khanani, Arshad M., et al.
Publicado: (2020)

Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole
por: Jackson, Timothy L., et al.
Publicado: (2017)

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009)

Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report
por: Guan, Goh Kian, et al.
Publicado: (2021)

Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
por: Grundmann, Eva, et al.
Publicado: (2023)

Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
por: Bevan, J S, et al.
Publicado: (2008)

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
por: Lybaert, Willem
Publicado: (2014)

Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy
por: Giri, Dinesh, et al.
Publicado: (2016)

Anomalous dynamics of water at the octopeptide lanreotide surface
por: Pinzan, Florian, et al.
Publicado: (2020)

Real world use of lanreotide in neuroendocrine tumors
por: Siddiqui, Zeba, et al.
Publicado: (2023)

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database
por: Fisher, Maxine D., et al.
Publicado: (2018)

Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
por: Lucas, T, et al.
Publicado: (2006)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Atomic structure of Lanreotide nanotubes revealed by cryo-EM
por: Pieri, Laura, et al.
Publicado: (2022)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
por: Klibanski, Anne, et al.
Publicado: (2009)

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
por: Ramage, John K, et al.
Publicado: (2011)

Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
por: Corda, Heike, et al.
Publicado: (2017)

Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis
por: Woodmansee, Whitney W., et al.
Publicado: (2018)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional
por: Johanson, Viktor, et al.
Publicado: (2012)

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
por: An, Zhenmei, et al.
Publicado: (2020)

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report
por: Van Fraeyenhove, Frank, et al.
Publicado: (2014)

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling
por: Ungefroren, Hendrik, et al.
Publicado: (2022)

Primary treatment of acromegaly with high-dose lanreotide: a case series
por: Wuster, Christian, et al.
Publicado: (2010)

The Use of Lanreotide in Polycystic Kidney Disease: A Single-Centre Experience
por: Treille, S., et al.
Publicado: (2014)

Lanreotide Autogel in the Treatment of Persistent Diarrhea following a Total Colectomy
por: Schoeters, Patrick, et al.
Publicado: (2015)

SAT-473 Acromegaly and Drug-Induced Parkinsonism Were Controlled by Lanreotide
por: Iwabuchi, Masayasu
Publicado: (2019)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
por: Yamaoka, Keiko, et al.
Publicado: (2021)

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis
por: Orlewska, Ewa, et al.
Publicado: (2014)

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
por: Chanson, Philippe, et al.
Publicado: (2008)

Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report
por: Aerts, Maridi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e6555rlg324uk4g0ckcqrppapa